On Monday, Exact Sciences Corp. (NASDAQ: EXAS) was -3.41% drop from the session before settling in for the closing price of $71.93. A 52-week range for EXAS has been $40.62 – $79.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 43.88% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 17.60%. With a float of $181.98 million, this company’s outstanding shares have now reached $184.77 million.
In an organization with 6600 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 72.3%, operating margin of -7.26%, and the pretax margin is -6.59%.
Exact Sciences Corp. (EXAS) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Exact Sciences Corp. stocks. The insider ownership of Exact Sciences Corp. is 1.51%, while institutional ownership is 97.36%. The most recent insider transaction that took place on Oct 08 ’24, was worth 65,030. In this transaction EVP, GM, Precision Oncology of this company sold 929 shares at a rate of $70.00, taking the stock ownership to the 12,758 shares. Before that another transaction happened on Oct 08 ’24, when Company’s Officer proposed sale 929 for $70.00, making the entire transaction worth $65,030.
Exact Sciences Corp. (EXAS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 17.60% per share during the next fiscal year.
Exact Sciences Corp. (NASDAQ: EXAS) Trading Performance Indicators
You can see what Exact Sciences Corp. (EXAS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Exact Sciences Corp. (EXAS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.58 million. That was inferior than the volume of 2.58 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 65.75%. Additionally, its Average True Range was 2.38.
During the past 100 days, Exact Sciences Corp.’s (EXAS) raw stochastic average was set at 92.00%, which indicates a significant increase from 55.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.21% in the past 14 days, which was lower than the 57.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $64.73, while its 200-day Moving Average is $58.80. However, in the short run, Exact Sciences Corp.’s stock first resistance to watch stands at $71.06. Second resistance stands at $72.64. The third major resistance level sits at $73.66. If the price goes on to break the first support level at $68.46, it is likely to go to the next support level at $67.43. Assuming the price breaks the second support level, the third support level stands at $65.85.
Exact Sciences Corp. (NASDAQ: EXAS) Key Stats
There are 184,530K outstanding shares of the company, which has a market capitalization of 12.84 billion. As of now, sales total 2,500 M while income totals -204,150 K. Its latest quarter income was 699,260 K while its last quarter net income were -15,810 K.
